Our target potential upside is almost 13% to 32% in the next 3-6 months.
Category: Stock Trades
Ligand Pharmaceuticals (NASDAQ: LGND) Could Move Higher in the Short-Term
by •
Our target potential upside is 16% to 26% in the next 3-6 months.
Concert Pharmaceuticals (NASDAQ: CNCE) Could Make an Upmove in the Near-Term
by •
Our target potential upside is nearly 11% to 33% in the next 3-5 months.
Sangamo Therapeutics (NASDAQ: SGMO) Just Broke Out on High Volume
by •
Our target potential upside is nearly 27% to 88% in the next 3-6 months.
Eli Lilly (NYSE: LLY) Just Broke Out
by •
Our target potential upside is nearly 7% to 13% in the next 3-6 months.
Equifax (NYSE: EFX) Just Broke Out on High Volume
by •
Our target potential upside is 5% to 17% in the next 4-6 months.
Constellation Pharmaceuticals (NASDAQ: CNST) Looks Ready for a Short-Term Price Bump
by •
Our target potential upside is 29% to 61% in the next 3-6 months.
Docusign (NASDAQ: DOCU) Broke Out and Looks Ready to Move Higher
by •
Our target trade offers nearly 2X to 4X more potential upside than downside.
Look For Lemonade (NYSE: LMND) to Continue Moving Higher in the Short-Term
by •
Our target potential upside is almost 10% to 22% in the next 3-6 months.
Spotify Technology (NYSE: SPOT) Just Broke Out
by •
Our target potential upside is 4% to 17% in the next 4-6 months.